
Brief intro:
- Author: Chunhui Huang, Xiao Zheng, Jiaxi Wu, Jiawei Li, Yingqi Lin, Yizhi Chen, Caijuan Li, Xichen Song, Wei Wang, Zhaoming Liu, Jianhao Wu, Jiale Gao, Zhuchi Tu, Zaijun Zhang, Liangxue Lai, Shihua Li, Xiao‐Jiang Li, Sen Yan
- Journal: MedComm (2020)
- Doi: https://www.doi.org/10.1002/mco2.70330
- Publication Date: 2025/9/14
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that lacks ideal models to comprehensively recapitulate its pathological features. TDP‐43 pathology, a hallmark of neurodegenerative diseases, plays a critical role in disease progression. Given the anatomical and physiological similarities between pig and human brains, large animal models offer a unique advantage in more accurately simulating patient‐specific disease characteristics. In this study, we rapidly established a TDP‐43‐induced neurodegenerative disease model in pigs through ear vein injection of the TDP‐43M337V virus. Disease progression was systematically evaluated using behavioral assessments and pathological analyses. This porcine model produced extremely severe motor dysfunction accompanied by significant muscle atrophy and fibrosis. Additionally, characteristic TDP‐43 pathological phenotypes were observed, including degeneration of spinal motor neurons and proliferation of glial cells in both the brain and spinal cord. Notably, TDP‐43M337V induction led to a significant upregulation of TMEM106B, SOD1, and APOE4 levels. This TDP‐43 porcine model recapitulates multiple key features of ALS and serves as a valuable complement to existing animal models, providing a robust platform for investigating TDP‐43‐related pathogenic mechanisms of TDP‐43 and developing effective therapeutics.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
